Management of Warfarin Therapy After INR Normalization

Recommended Management Plan

The American College of Cardiology recommends restarting warfarin therapy immediately at a lower maintenance dose than the patient was previously taking, with close monitoring to achieve the target therapeutic range, in patients with a normalized INR after severe elevation 1
The initial restart dose should be approximately 50-75% of the patient's pre-hospitalization maintenance dose, and a loading dose should not be used to avoid increasing the risk of hemorrhagic complications without providing faster protection against thrombi formation 1
Monitor INR closely, checking again in 3-4 days after restarting therapy, and adjust subsequent doses based on INR response, with a goal of achieving the appropriate therapeutic range based on the patient's indication for anticoagulation 2

Elderly patients typically require lower warfarin doses, approximately 1 mg/day less than younger individuals, due to a higher bleeding risk at any given INR level 1

For most indications, including atrial fibrillation, the target INR range is between 2.0-3.0, according to the American College of Cardiology and other guidelines 3

Continuing to withhold warfarin places the patient at risk for thromboembolism based on their underlying condition requiring anticoagulation, and the risk of thromboembolism increases significantly when patients remain subtherapeutic 1, 4

Check INR 3-4 days after restarting warfarin, and once stable, check INR weekly until consistent therapeutic range is achieved, according to the American College of Chest Physicians 2

The American College of Cardiology recommends investigating and addressing the cause of the initial INR elevation to prevent recurrence, and documenting the reason for the initial INR elevation to prevent similar occurrences 3
Elderly patients have a higher bleeding risk at any given INR level and require more cautious management, and if the patient had bleeding complications during the initial INR elevation, consider targeting the lower end of the therapeutic range 1, 3